184 related articles for article (PubMed ID: 26574637)
1. Immunohistochemistry Biomarkers in Nonmuscle Invasive Bladder Cancer.
Ranzi AD; da Silva JN; Graziottin TM; Annels N; Bica CG
Appl Immunohistochem Mol Morphol; 2017 Mar; 25(3):178-183. PubMed ID: 26574637
[TBL] [Abstract][Full Text] [Related]
2. Ki-67 is an independent indicator in non-muscle invasive bladder cancer (NMIBC); combination of EORTC risk scores and Ki-67 expression could improve the risk stratification of NMIBC.
Ding W; Gou Y; Sun C; Xia G; Wang H; Chen Z; Tan J; Xu K; Qiang D
Urol Oncol; 2014 Jan; 32(1):42.e13-9. PubMed ID: 24360660
[TBL] [Abstract][Full Text] [Related]
3. Combination of CK20 and Ki-67 immunostaining analysis predicts recurrence, progression, and cancer-specific survival in pT1 urothelial bladder cancer.
Bertz S; Otto W; Denzinger S; Wieland WF; Burger M; Stöhr R; Link S; Hofstädter F; Hartmann A
Eur Urol; 2014 Jan; 65(1):218-26. PubMed ID: 22633802
[TBL] [Abstract][Full Text] [Related]
4. Novel biomarkers to predict response and prognosis in localized bladder cancer.
Lucca I; de Martino M; Klatte T; Shariat SF
Urol Clin North Am; 2015 May; 42(2):225-33, ix. PubMed ID: 25882564
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic and prognostic value of bladder cancer-related transcript markers in urine.
Schmidt J; Propping C; Siow WY; Lohse-Fischer A; Toma M; Baldauf-Twelker A; Hakenberg OW; Wirth MP; Fuessel S
J Cancer Res Clin Oncol; 2016 Feb; 142(2):401-14. PubMed ID: 26328914
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of p53 and Ki-67 expression in intermediate-risk patients with nonmuscle-invasive bladder cancer receiving adjuvant intravesical mitomycin C therapy.
Seo HK; Cho KS; Chung J; Joung JY; Park WS; Chung MK; Lee KH
Urology; 2010 Aug; 76(2):512.e1-7. PubMed ID: 20579709
[TBL] [Abstract][Full Text] [Related]
7. Do molecular biomarkers have prognostic value in primary T1G3 bladder cancer treated with bacillus Calmette-Guerin intravesical therapy?
Park J; Song C; Shin E; Hong JH; Kim CS; Ahn H
Urol Oncol; 2013 Aug; 31(6):849-56. PubMed ID: 21782482
[TBL] [Abstract][Full Text] [Related]
8. Prognostic Significance of CREB-Binding Protein and CD81 Expression in Primary High Grade Non-Muscle Invasive Bladder Cancer: Identification of Novel Biomarkers for Bladder Cancer Using Antibody Microarray.
Lee MS; Kim JH; Lee JS; Yun SJ; Kim WJ; Ahn H; Park J
PLoS One; 2015; 10(4):e0125405. PubMed ID: 25915404
[TBL] [Abstract][Full Text] [Related]
9. Tissue biomarkers in nonmuscle-invasive bladder cancer: any role in clinical practice?
Bruchbacher A; Soria F; Hassler M; Shariat SF; D'Andrea D
Curr Opin Urol; 2018 Nov; 28(6):584-590. PubMed ID: 30188332
[TBL] [Abstract][Full Text] [Related]
10. Follow-up in non-muscle-invasive bladder cancer-International Bladder Cancer Network recommendations.
Kassouf W; Traboulsi SL; Schmitz-Dräger B; Palou J; Witjes JA; van Rhijn BW; Grossman HB; Kiemeney LA; Goebell PJ; Kamat AM
Urol Oncol; 2016 Oct; 34(10):460-8. PubMed ID: 27368880
[TBL] [Abstract][Full Text] [Related]
11. Introduction and first clinical application of a simplified immunohistochemical validation system confirms prognostic impact of KI-67 and CK20 for stage T1 urothelial bladder carcinoma: single-center analysis of eight biomarkers in a series of three hundred six patients.
Otto W; Denzinger S; Fritsche HM; Burger M; Rößler W; Bertz S; May M; Hartmann A; Hofstädter F; Wieland WF; Eder F
Clin Genitourin Cancer; 2013 Dec; 11(4):537-44. PubMed ID: 23850551
[TBL] [Abstract][Full Text] [Related]
12. Predictive Markers for the Recurrence of Nonmuscle Invasive Bladder Cancer Treated with Intravesical Therapy.
Miyata Y; Sakai H
Dis Markers; 2015; 2015():857416. PubMed ID: 26681820
[TBL] [Abstract][Full Text] [Related]
13. CK20 and Ki-67 as significant prognostic factors in human bladder carcinoma.
Ye YK; Bi XC; He HC; Han ZD; Dai QS; Liang YX; Zeng GH; Qin WJ; Chen ZN; Zhong WD
Clin Exp Med; 2010 Sep; 10(3):153-8. PubMed ID: 20069333
[TBL] [Abstract][Full Text] [Related]
14. Clinical Significance of Substaging and HER2 Expression in Papillary Nonmuscle Invasive Urothelial Cancers of the Urinary Bladder.
Lim SD; Cho YM; Choi GS; Park HK; Paick SH; Kim WY; Kim SN; Yoon G
J Korean Med Sci; 2015 Aug; 30(8):1068-77. PubMed ID: 26240484
[TBL] [Abstract][Full Text] [Related]
15. Monitoring high-risk bladder cancer.
Schwentner C; Stenzl A; Gakis G
Curr Opin Urol; 2012 Sep; 22(5):421-6. PubMed ID: 22814882
[TBL] [Abstract][Full Text] [Related]
16. New and contemporary markers of prognosis in nonmuscle invasive urothelial cancer.
Ather MH; Nazim SM
Korean J Urol; 2015 Aug; 56(8):553-64. PubMed ID: 26279824
[TBL] [Abstract][Full Text] [Related]
17. Cell-cycle markers do not improve discrimination of EORTC and CUETO risk models in predicting recurrence and progression of non-muscle-invasive high-grade bladder cancer.
Passoni N; Gayed B; Kapur P; Sagalowsky AI; Shariat SF; Lotan Y
Urol Oncol; 2016 Nov; 34(11):485.e7-485.e14. PubMed ID: 27637323
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic, prognostic and surveillance urinary markers in nonmuscle invasive bladder cancer: any role in clinical practice?
Soria F; D'Andrea D; Pohar K; Shariat SF; Lotan Y
Curr Opin Urol; 2018 Nov; 28(6):577-583. PubMed ID: 30157039
[TBL] [Abstract][Full Text] [Related]
19. Alteration in urinary matrix metalloproteinase-9 to tissue inhibitor of metalloproteinase-1 ratio predicts recurrence in nonmuscle-invasive bladder cancer.
Durkan GC; Nutt JE; Marsh C; Rajjayabun PH; Robinson MC; Neal DE; Lunec J; Mellon JK
Clin Cancer Res; 2003 Jul; 9(7):2576-82. PubMed ID: 12855633
[TBL] [Abstract][Full Text] [Related]
20. Ras association domain family 1A: a promising prognostic marker in recurrent nonmuscle invasive bladder cancer.
Kim JS; Chae Y; Ha YS; Kim IY; Byun SS; Yun SJ; Kim WJ
Clin Genitourin Cancer; 2012 Jun; 10(2):114-20. PubMed ID: 22382007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
